Abeona Therapeutics Inc. (NASDAQ:ABEO) was up 5.6% on Monday . The stock traded as high as $2.84 and last traded at $2.84, with a volume of 51,334 shares. The stock had previously closed at $2.69.

Several equities research analysts recently weighed in on ABEO shares. Maxim Group reaffirmed a “buy” rating on shares of Abeona Therapeutics in a report on Tuesday, May 24th. FBR & Co reaffirmed a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a report on Sunday, May 22nd. Rodman & Renshaw reiterated a “buy” rating and issued a $17.00 price objective on shares of Abeona Therapeutics in a research report on Wednesday, May 18th. Finally, Zacks Investment Research upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research report on Wednesday, April 27th.

The stock has a 50-day moving average of $2.56 and a 200-day moving average of $2.64. The firm’s market capitalization is $92.48 million.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.04. On average, equities analysts expect that Abeona Therapeutics Inc. will post ($0.59) EPS for the current fiscal year.

A hedge fund recently raised its stake in Abeona Therapeutics stock. Royce & Associates LLC raised its stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned about 0.92% of Abeona Therapeutics worth $1,007,000 as of its most recent filing with the SEC.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.